Kinnate is a biopharmaceutical company advancing a pipeline of precision oncology therapeutics to treat patients with genomically. Founded by Eric A Murphy and Stephen Kaldor in 2018, Kinnate Biopharma is backed by investors that include OrbiMed, Foresite Capital, Nextech Invest, Vida Ventures, and Eshelman Ventures and is headquartered in San Diego.